VANCOUVER, BC--(Marketwire - July 28, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) announced today that it is collaborating with Makerere University in Kampala, Uganda to evaluate the efficacy in animals of more than 20 proprietary drug candidates as potential treatments for Leishmaniasis in humans. Drug resistance has greatly reduced the effectiveness of existing Leishmaniasis treatments.
